Cite
H19 in Serum Extracellular Vesicles Reflects Resistance to AR Axis-targeted Therapy Among CRPC Patients.
MLA
Taku Kato, et al. “H19 in Serum Extracellular Vesicles Reflects Resistance to AR Axis-Targeted Therapy Among CRPC Patients.” Cancer Genomics & Proteomics (1109-6535), vol. 20, no. 5, Sept. 2023, pp. 456–68. EBSCOhost, https://doi.org/10.21873/cgp.20397.
APA
Taku Kato, Kyojiro Kawakami, Kosuke Mizutani, Tatsuya Ando, Yasuhiro Sakai, Kouhei Sakurai, Shohei Toyota, Hidetoshi Ehara, Hiroyasu Ito, & Masafumi Ito. (2023). H19 in Serum Extracellular Vesicles Reflects Resistance to AR Axis-targeted Therapy Among CRPC Patients. Cancer Genomics & Proteomics (1109-6535), 20(5), 456–468. https://doi.org/10.21873/cgp.20397
Chicago
Taku Kato, Kyojiro Kawakami, Kosuke Mizutani, Tatsuya Ando, Yasuhiro Sakai, Kouhei Sakurai, Shohei Toyota, Hidetoshi Ehara, Hiroyasu Ito, and Masafumi Ito. 2023. “H19 in Serum Extracellular Vesicles Reflects Resistance to AR Axis-Targeted Therapy Among CRPC Patients.” Cancer Genomics & Proteomics (1109-6535) 20 (5): 456–68. doi:10.21873/cgp.20397.